<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309372</url>
  </required_header>
  <id_info>
    <org_study_id>R01HL126557</org_study_id>
    <nct_id>NCT02309372</nct_id>
  </id_info>
  <brief_title>Depression Therapy to Improve Cardiovascular Risk in HIV</brief_title>
  <official_title>A Randomized, Controlled Pilot Trial Assessing the Utility of Cognitive Behavioral Therapy to Improve Endothelial Function and Reduce Inflammation in Depressed, Virologically-Suppressed, Antiretroviral-Treated, HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will determine if depression treatment will reduce cardiovascular risk in
      HIV-infected patients already receiving HIV treatments. Half of the participants will undergo
      a specific computerized depression treatment with the other half receiving usual care from
      their HIV providers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study will be met by performing a 24-week, randomized, controlled,
      single-blinded, two-arm, parallel group, pilot trial at a single center. A total of 200
      subjects may be screened to identify 110 participants to be enrolled and randomized. These
      participants will be ≥ 18 years old, have been receiving antiretroviral therapy for at least
      one year with an HIV viral load &lt; 75 copies/mL at screening, and have major depression using
      the PHQ-9 questionnaire. These participants will be randomized 1:1 to either depression
      treatment with the Beating-the-Blues cognitive behavioral therapy program (N=55) or usual
      care (N=55).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Brachial Artery Flow-mediated Dilation From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12 of participation</time_frame>
    <description>Changes in flow-mediated dilation of the brachial artery from baseline to week 12. This is calculated by the FMD value at Week 12 minus the FMD value at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Circulating IL-6 From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Interleukin-6 (IL-6) is a measure of systemic inflammation. This is calculated by the IL-6 value at Week 12 minus the IL-6 value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hsCRP From Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>hsCRP (high sensitivity C-reactive protein) is a measure of systemic inflammation. This is calculated by the hsCRP value at Week 12 minus the hsCRP value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-dimer From Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>D-dimer is a measure of systemic coagulation. This is calculated by the D-dimer value at Week 12 minus the D-dimer value at baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Depression</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Cognitive Behavioral Therapy (CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Beating the Blues</intervention_name>
    <description>Computerized depression treatment intervention</description>
    <arm_group_label>Cognitive Behavioral Therapy (CBT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection, documented by both: (1) any licensed rapid HIV test or HIV enzyme
             test kit at any time prior to study entry and (2) by at least one detectable HIV-1
             antigen or at least one detectable plasma HIV-1 RNA viral load

          -  Age equal to or greater than 18 years

          -  Receipt of antiretroviral therapy of any kind for at least 360 days prior to screening

        Note: Interruptions in ART of up to 14 days total during the 360 days prior to screening
        are allowed

          -  HIV-1 RNA level &lt; 75 copies/mL at screening

        NOTE: There are no CD4 cell count eligibility criteria for this trial

          -  For women who are still of reproductive potential, a negative urine pregnancy test

          -  Depression as defined by having a score ≥ 10 on the PHQ-9 questionnaire

        Exclusion Criteria:

          -  Inability to complete written, informed consent

          -  Incarceration at the time of any study visit

          -  Active suicidality, as determined by the patient's HIV provider or social worker
             following a positive response (1, 2, or 3) to PHQ-9 Item #9 and a positive response
             (yes) to one or more of the three questions on the Patient Suicidality Form (with last
             suicide attempt within the past ten years)

          -  Diagnosed vascular disease (documented history of angina pectoris, coronary disease,
             peripheral vascular disease, cerebrovascular disease, aortic aneurysm, or otherwise
             known atherosclerotic disease)

          -  History of congestive heart failure, even if currently compensated

          -  Diagnosed disease or process, besides HIV infection, associated with increased
             systemic inflammation (including, but not limited to, systemic lupus erythematosis,
             inflammatory bowel diseases, other collagen vascular diseases)

        Note: Hepatitis B or C co-infections are NOT exclusionary

          -  Known or suspected malignancy requiring systemic treatment within 180 days of
             screening

        NOTE: Localized treatment for skin cancers is not exclusionary

          -  History of Raynaud's phenomenon

          -  History of cardiac arrhythmias or cardiomyopathy

          -  Uncontrolled hyperthyroidism or hypothyroidism, defined as TSH values outside of the
             local reference range on most recent clinical assessment

          -  History of carotid bruits

          -  Systolic blood pressure &gt; 160 mmHg or diastolic blood pressure &gt; 110 mmHg at screening

          -  Screening estimated glomerular filtration rate (eGFR) &lt; 50 mL/min/1.732 (using the
             2009 CKD-EPI equation) using a serum creatinine level measured at screening

          -  Screening glucose ≥ 140 mg/dL or hemoglobin A1c &gt; 8.0%

          -  Screening total cholesterol &gt; 240 mg/dL

          -  Therapy for serious medical illnesses within 14 days prior to screening

        Note: Therapy for serious medical illnesses that overlaps with a main study visit will
        result in postponement of that study visit until the course of therapy is completed;
        postponement outside of the allowed study visit timeframe will result in study
        discontinuation

          -  Pregnancy or breastfeeding during the course of the study

          -  Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids
             (of any dose), or anabolic steroids at screening

        Note: Physiologic testosterone replacement therapy or topical steroids is not exclusionary.
        Inhaled/nasal steroids are not exclusionary as long as the participant is not also
        receiving HIV protease inhibitors

          -  Active drug use or dependence that, in the opinion of the investigator, would
             interfere with adherence to study requirements

          -  History of schizophrenia or bipolar disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir K Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesse C Stewart, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Health University Hospital, Indiana Clinical Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <results_first_submitted>June 16, 2020</results_first_submitted>
  <results_first_submitted_qc>July 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2020</results_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Samir K Gupta, MD, MS</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02309372/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cognitive Behavioral Therapy (CBT)</title>
          <description>Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
Beating the Blues: Computerized depression treatment intervention</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cognitive Behavioral Therapy (CBT)</title>
          <description>Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
Beating the Blues: Computerized depression treatment intervention</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="9.8"/>
                    <measurement group_id="B2" value="45.6" spread="11.9"/>
                    <measurement group_id="B3" value="45.1" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Brachial Artery Flow-mediated Dilation From Baseline to Week 12</title>
        <description>Changes in flow-mediated dilation of the brachial artery from baseline to week 12. This is calculated by the FMD value at Week 12 minus the FMD value at baseline.</description>
        <time_frame>Baseline and Week 12 of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy (CBT)</title>
            <description>Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
Beating the Blues: Computerized depression treatment intervention</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brachial Artery Flow-mediated Dilation From Baseline to Week 12</title>
          <description>Changes in flow-mediated dilation of the brachial artery from baseline to week 12. This is calculated by the FMD value at Week 12 minus the FMD value at baseline.</description>
          <units>absolute percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="2.65"/>
                    <measurement group_id="O2" value="0.29" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.28</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Circulating IL-6 From Baseline to Week 12</title>
        <description>Interleukin-6 (IL-6) is a measure of systemic inflammation. This is calculated by the IL-6 value at Week 12 minus the IL-6 value at baseline.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Participants who had blood samples available for analysis at both baseline and Week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy (CBT)</title>
            <description>Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
Beating the Blues: Computerized depression treatment intervention</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Circulating IL-6 From Baseline to Week 12</title>
          <description>Interleukin-6 (IL-6) is a measure of systemic inflammation. This is calculated by the IL-6 value at Week 12 minus the IL-6 value at baseline.</description>
          <population>Participants who had blood samples available for analysis at both baseline and Week 12</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="8.71"/>
                    <measurement group_id="O2" value="1.24" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in hsCRP From Baseline to Week 12</title>
        <description>hsCRP (high sensitivity C-reactive protein) is a measure of systemic inflammation. This is calculated by the hsCRP value at Week 12 minus the hsCRP value at baseline.</description>
        <time_frame>12 weeks</time_frame>
        <population>Participants who had blood samples available for analysis at both baseline and Week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy (CBT)</title>
            <description>Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
Beating the Blues: Computerized depression treatment intervention</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in hsCRP From Baseline to Week 12</title>
          <description>hsCRP (high sensitivity C-reactive protein) is a measure of systemic inflammation. This is calculated by the hsCRP value at Week 12 minus the hsCRP value at baseline.</description>
          <population>Participants who had blood samples available for analysis at both baseline and Week 12</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="3.89"/>
                    <measurement group_id="O2" value="1.06" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in D-dimer From Baseline to Week 12</title>
        <description>D-dimer is a measure of systemic coagulation. This is calculated by the D-dimer value at Week 12 minus the D-dimer value at baseline.</description>
        <time_frame>12 weeks</time_frame>
        <population>Participants who had blood samples available for analysis at both baseline and Week 12</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy (CBT)</title>
            <description>Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
Beating the Blues: Computerized depression treatment intervention</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in D-dimer From Baseline to Week 12</title>
          <description>D-dimer is a measure of systemic coagulation. This is calculated by the D-dimer value at Week 12 minus the D-dimer value at baseline.</description>
          <population>Participants who had blood samples available for analysis at both baseline and Week 12</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="466"/>
                    <measurement group_id="O2" value="-10.26" spread="651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cognitive Behavioral Therapy (CBT)</title>
          <description>Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
Beating the Blues: Computerized depression treatment intervention</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated creatine kinase</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Arthroplasty of toe</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samir K. Gupta, MD, MS</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>3172747926</phone>
      <email>sgupta1@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

